Niacin in the Treatment of Hyperlipidemias in Light of New Clinical Trials: Has Niacin Lost its Place?

Niacin is considered to be a powerful drug for the treatment of lipid and lipoprotein abnormalities connected with “residual cardiovascular risk”, which persist in high-risk patients even when the target goals of LDL-C are achieved with statin therapy. Recent large randomized clinical studies – AIM-...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeman, Miroslav, Vecka, Marek, Perlík, František, Hromádka, Róbert, Staňková, Barbora, Tvrzická, Eva, Žák, Aleš
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2015
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4523006/
https://www.ncbi.nlm.nih.gov/pubmed/26210594
http://dx.doi.org/10.12659/MSM.893619

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4523006/
https://www.ncbi.nlm.nih.gov/pubmed/26210594
http://dx.doi.org/10.12659/MSM.893619

Ejemplares similares